Shionogi To Divest Contract Manufacturer To Focus On Prescription Business
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Shionogi's board of directors agreed to transfer wholly owned Bushu Pharmaceuticals to private investment fund TMC BUYOUT1, a subsidiary of Tokio Marine Capital beginning March 31. Bushu is the second-largest pharmaceutical contract manufacturer in Japan
You may also be interested in...
Shionogi Looks Beyond Crestor to HIV Platform
The company's leading HIV candidate, S-349572, is an integrase inhibitor that had the strongest efficacy ever reported for the class in a Phase IIa study.
Shionogi Looks Beyond Crestor to HIV Platform
The company's leading HIV candidate, S-349572, is an integrase inhibitor that had the strongest efficacy ever reported for the class in a Phase IIa study.
Shionogi Looks Beyond Crestor to HIV Platform
TOKYO - Shionogi still has a few years to reap the benefits of Crestor royalties from AstraZeneca, but the looming generic substitution of rival Lipitor is forcing the company to prepare for a slowdown of its blockbuster drug. But according to Macquarie Equities Research, revised ex-U.S. Crestor prospects, strong pipeline prospects and recent launches could position Shionogi well in the near term